This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Jun 1;10(6):704-705.

doi: 10.1001/jamaoncol.2023.7262.

Immunotherapy in Gastric Cancer-Choosing Methods or Results

Thierry Alcindor^{1

2}

Affiliations

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 38573642
DOI: 10.1001/jamaoncol.2023.7262

Immunotherapy in Gastric Cancer-Choosing Methods or Results

Thierry Alcindor. JAMA Oncol. 2024.

. 2024 Jun 1;10(6):704-705.

doi: 10.1001/jamaoncol.2023.7262.

Author

Thierry Alcindor^{1

2}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 38573642
DOI: 10.1001/jamaoncol.2023.7262

No abstract available

PubMed Disclaimer

Comment in

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C; PRODIGE 59-FFCD 1707-DURIGAST Investigators/Collaborators. Tougeron D, et al. JAMA Oncol. 2024 Jun 1;10(6):709-717. doi: 10.1001/jamaoncol.2024.0207. JAMA Oncol. 2024. PMID: 38573643 Free PMC article. Clinical Trial.

Similar articles

Immunological contributions to the management of gastric cancer.
Guillou PJ, Monson JR. Guillou PJ, et al. Hepatogastroenterology. 1989 Apr;36(2):86-91. Hepatogastroenterology. 1989. PMID: 2659484 Review. No abstract available.
Remnant gastric cancer: a neglected group with high potential for immunotherapy.
Ramos MFKP, Pereira MA, de Castria TB, Ribeiro RRE, Cardili L, de Mello ES, Zilberstein B, Ribeiro-Júnior U, Cecconello I. Ramos MFKP, et al. J Cancer Res Clin Oncol. 2020 Dec;146(12):3373-3383. doi: 10.1007/s00432-020-03322-7. Epub 2020 Jul 15. J Cancer Res Clin Oncol. 2020. PMID: 32671505 Free PMC article.
Immunotherapeutic advances in gastric cancer.
Yoneda A, Kuroki T, Eguchi S. Yoneda A, et al. Surg Today. 2021 Nov;51(11):1727-1735. doi: 10.1007/s00595-021-02236-2. Epub 2021 Feb 15. Surg Today. 2021. PMID: 33590326 Review.
Role of adjuvant chemotherapy and immunotherapy in gastric cancer.
Labianca R, Panvini D. Labianca R, et al. Pathol Biol (Paris). 1993 Jan;41(1):80-1. Pathol Biol (Paris). 1993. PMID: 8316482 No abstract available.
[Current status and trends of perioperative immunotherapy for gastric cancer].
Zhu YF, Hu JK. Zhu YF, et al. Zhonghua Wai Ke Za Zhi. 2025 Jul 1;63(7):575-580. doi: 10.3760/cma.j.cn112139-20250315-00132. Zhonghua Wai Ke Za Zhi. 2025. PMID: 40443332 Review. Chinese.

See all similar articles

References

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information